CEO Gerald Mattys of Tactile Systems Technology Inc (NASDAQ:TCMD), a manufacturer and provider of products focused on treating chronic illnesses in the home setting, says his company has opportunities ahead in the lymphedema and wound care markets.
We built the platform of directly serving patients at home because we believe it could be leveraged into other clinical indications. We have shown that it can be done by our acquisition of ACTitouch. Before ACTitouch, we were a lymphedema only company. We acquired the ACTitouch and now are a lymphedema and wound-care company. We do see this as a platform along with reimbursement “know-how” and direct sales as all aspects that we can leverage.
Having said that, we are in a very under-penetrated market right now with lymphedema, and with awareness just increasing as we speak, we see a huge opportunity in front of us to continue pursuing the lymphedema market in the United States. We believe this represents and opportunity for Tactile Medical to continue growing at 20%-plus revenue growth per year going forward.
Our longer-term strategy is to leverage the platform, but in the short term, we see the lymphedema and wound market opportunities as very compelling and will be the primary focus areas of our growth plans in the coming years.
Sirius XM Radio Inc (SIRI) on High-Growth Trajectory, Generating $130 Per Listener Per Year Compared to Pandora’s $8
November 12, 2013
EMC Corporation (EMC) Has 10% Revenue Growth, 16% EPS Growth Potential with Portfolio of Data Storage Solutions
September 18, 2013
Agrium Inc. (USA) (AGU) Has Potential to Grow Cash Flow to $1 Billion and Dividend to $4 Per Share
July 25, 2014
Apple Inc. (AAPL) Has Potential for $90 Billion Free Cash Flow This Year
November 10, 2015
National Health Investors Inc (NHI) Averages 8% Dividend Growth Per Year, Updates FFO Guidance from $3.48 to $3.54
July 29, 2013
